Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL324 in severe COVID-19
NCT04519424Phase 2Withdrawn
- Sponsor
- CSL Limited
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of anumigilimab in coronavirus disease 2019 (COVID-19), sponsored by CSL Limited. Planned start Sep 2020; status: withdrawn.
02
Drugs
anumigilimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04519424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519424.